Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
62 participants
INTERVENTIONAL
2008-11-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The incidence of diabetes is rising constantly. According to the WHO projections, the population of diabetics will double by 2025. In France, the current population of diabetics is estimated at 2.5 millions persons. The cause of death in diabetics involves a cardiovascular condition in approximately 65-80% of the cases. The leading event is myocardial infarction. The prevalence of silent myocardial ischemia (SMI) in diabetics varies widely from 10 to 30%. The prognosis of SMI is closely dependent on the presence or not of angiographically significant coronary artery stenosis - CAS (patients with SMI and CAS\>70% show 31% of major cardiac events at 41±24 months vs only 1.4% in patients with SMI and no CAS\>70%). It seems therefore important to identify diabetic patients with SMI and CAS especially knowing that endovascular or surgical treatments are available and can potentially improve the prognosis of such patients.
Myocardial Perfusion Scintigraphy (MPS) is widely prescribed to detect coronary stenosis. It has a high sensitivity (90%) but an intermediate specificity (75%), providing a significant amount of false positive cases. Such false positive cases are usually followed with unnecessary coronary angiographies. Myocardial Perfusion Stress MRI (MRI) has been recently developed and shows promising preliminary results (equivalent sensitivity, higher specificity compared to MPS) for the identification of coronary artery stenosis. Few studies directly compare MRI and MPS in the general population, none in the diabetic population.
Principal objective: To evaluate and compare diagnostic performances of MRI and MPS for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease.
Secondary objective:
* Cost efficacy analysis for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease.
* Impact of clinical information on MRI and MPS diagnostic performances.
Design:. Prospective, monocentric study, where MRI and MPS will be assessed in a centralised manner by 2 independent blinded readers (2 readers for each technique) and compared to coronary angiography (Gold Standard, assessed by 2 independent blinded readers).
Patient selection: Patient with diabetes (type 1 or type 2), free of known coronary disease, addressed for MPS.
Inclusion period length: 24 months
Follow up period length: 2 days
Principal judgement criteria:
Coronary angiography: positive diagnosis of CAS if stenosis \>50% on the left coronary artery (trunk) or stenosis \>70% on the IVA (inter ventricular artery), LCx (circumflex artery) or RCA (right coronary artery) and branches.
MPS : positive diagnosis of CAS based on the following criteria : severity perfusion index, reversibility, contractility anomalies, signal attenuation due to patient morphology.
MRI : positive diagnosis of CAS based on an algorithm including the following criteria : first pass perfusion defect at stress, reversibility at rest, Myocardial Delayed Enhancement.
Number of necessary patients: 165
Expected results: An assessment of MRI performances compared to MPS for the diagnosis of coronary insufficiency in diabetic patients free of known coronary disease that will help improve diagnostic strategy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy
* Diabetic patients
* Coronary insufficiency
MRI
MRI = Myocardial Perfusion Stress
MPS
MPS = Myocardial Perfusion Scintigraphy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
MRI = Myocardial Perfusion Stress
MPS
MPS = Myocardial Perfusion Scintigraphy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with health care coverage ( social security or universal health coverage - CMU)
* Patient who had a prior medical examination
* Diabetic patient (type 1 or type 2) with no known coronary artery disease, addressed for myocardial scintigraphy
* Patient who was informed of objectives and constraints of the study and having given his consent in writing
Exclusion Criteria
* Patients with known coronary disease (myocardial infarction, unstable angina, history of coronary artery disease)
* Patient with contra-indication for MRI claustrophobia, metallic foreign body in the eye, pacemakers, mechanical heart valve laid before 1985 Patient with specific contra-indication to vasodilators
* Severe hypotension \< 90 mmHg
* Hypersensitivity to adenosine or dipyridamole
* Bronchial asthma, chronic obstructive pulmonary disease with obvious bronchospasm. Severe and known pulmonary artery hypertension
* Atrioventricular 2nd or 3rd degree blocks, long QT syndrome
* Tight known carotid artery stenosis (70% NASCET criterion), with no possible vascular substitution
* Patient with contra-indication to cardiac stimulation
* Unstable hemodynamic state and / or unstable angina not stabilized by drug treatment and/or decompensated or severe heart failure
* Known comorbidities : pregnancy and lactation, tight aortic valve or mitral valve stenosis, severe left-right shunt, severe pericarditis or abundant pericardial effusion
* Contra-indication to coronary angiography
* Renal failure with creatinine clearance \< 30 ml / min
* Hypersensitivity to contrast agents that resulted in a serious complication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Michel SERFATY, PHU
Role: PRINCIPAL_INVESTIGATOR
ASSISTANCE PUBLIQUE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Bichat
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOR07022
Identifier Type: OTHER
Identifier Source: secondary_id
P070149
Identifier Type: -
Identifier Source: org_study_id